Welcome
to
the
future
of
neurotherapeutics.
OUR MISSION
At Sculpta Bio, we are dedicated to developing effective treatments for neurodegeneration, mental health, and the aging brain, enabling longer, healthier lives for all. Around the world, millions are losing memories, identities, and futures to diseases we still cannot stop. It is a crisis growing faster than science has kept pace.
But, the past does not have to define our future.
Sculpta is forging a bold new path in neurotherapeutic drug development, powered by cutting edge technology, scientific excellence, and a relentless spirit of urgency. Humanity cannot wait any longer.
Discover how we are challenging the status quo by reshaping the future of brain health.
A BOLD, NEW APPROACH
Protein sculpting therapeutics
Other companies try to drug proteins in the brain to treat disease.
We change them.
Sculpta is the pioneer in protein sculpting therapeutics, drugs that change the structure and function of disease-causing proteins in the brain using programmable RNA medicines. We move beyond “up/down” genomic medicines, offering safer, more specific, and more effective therapies for devastating brain disorders, brought to patients faster.
ADVANCED NEURAL TISSUE ANALYSIS
Quality over quantity
Single cell genomics has revolutionized biological discovery, yet quality is often sacrificed for quantity. The most widely used platforms capture only the very ends of transcripts. AI models trained on this inaccurate data are destined to fail.
Sculpta’s platform captures full-length transcripts, powering our ATLAS AI-platform that is driving unique insights into the neurobiology of human disease.
ACCURATE PRE-CLINICAL MODELS
Human models for human disease
Traditional animal models often fail to capture human-specific disease mechanisms. Our best-in-class human brain organoids platform enables us to discover the root causes of disease and test therapeutics in living human neurons.
Neal Amin, MD, PhD
Founder | CEO
Joshua Berlind
Scientist
Amina Khan, PhD
Research Associate
Bryan van Nimwegen, PhD
Computational Biologist
Mislav Acman
Senior Computational Biologist
Backed by
April 2025
New Publication in Nature
Neal Amin, CEO
March 2025
Sculpta Closes $2.6M Funding Round
Sculpta has successfully secured $2.6M in pre-seed funding from six venture capital groups and six angels to accelerate the the development of protein sculpting therapies for devastating brain disorders.